All four are in order, fastest above slowest — every timeframe pointing the same way.
Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.
The base has run 10.0 weeks and fell 22% from its ceiling at its deepest. The pivot is $42.50, and the stock closed 9.2% below it. Its relative strength rating is 91.
Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.
- Earningstentativein 80dQuarterly earningsFeb 4, 2027
On average 7.6% either way across its last 8 reports.
Checking your subscription…
Close before the report day to close after it, so it holds whether the company reported before the open or after the close.
Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.
What the numbers say
- Good: Revenue +2135.6% year over year, +2335.6% on the quarter
- Weak: Net loss $192M, wider than $190M last quarter
- Good: Cash generating: operating cash flow $594M, free cash flow $594M
- Weak: Share count +6.1% in a year: dilution
- Good: Net cash $1.64B · cash $1.64B
From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.
None of the tracked funds held or sold it in their latest filings.
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Sold: Pulik Richard, Venker Eric, Epperly Melissa B,, Fitzgerald Meghan, Sukhatme Mayukh, MANCHESTER KEITH S, Gold Daniel Allen, QVT Financial LP.
Not counted above: 57 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.
From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.
6 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.
These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.
Checking your subscription…
Checking your subscription…
The most recent of 2 completed bases.
Checking your subscription…